The $30 million toe in the water: GLP-1 therapies

The Endocrine Society and women's health researchers worldwide have led a years-long international effort to rename Polycystic Ovary Syndrome, now often termed PMOS, to highlight its metabolic basis and aid diagnosis and treatment. According to the report, the shift seeks to move focus beyond ovarian cysts to underlying insulin resistance and hormone imbalances, potentially opening pathways for better management including emerging GLP-1 therapies.

Polycystic Ovary Syndrome, commonly known as PCOS, has recently undergone a name change folllowing a years-long international effort led by the Endocrine Society and women's health researchers worldwide. The novel terminology aims to update how clinicians care for women struggling with the disease.

Why 4,000 unsold units became the prize

Women with PMOS symptoms can experience a range of health issues, including difficulty maintaining a healthy weight, mental health struggles, excessive hair growth or loss, and loss of reproductive functions such as missed periods and anovulation. However, obtaining a diagnosis can be a significant challenge due to the wide variety of symptoms.

Research indicates that, on average,it takes one year and at least three doctor's visits to receive an official PMOS diagnosis, with some women undergoing years of trial and error before their symptoms are correctly attributed to the syndrome.

Who is the unnamed buyer?

The name change is partly intended to help women acces treatment for the underlying metabolic and cellular dysfunction that causes the range of PMOS symptoms. Experts note that an excess of insulin in patients with PMOS can confuse the ovaries to produce too much testosterone, which drives many of the syndrome's manifestations.

In studies involving GLP-1 weight loss medications, such as those produced by Novo Nordisk and Eli Lilly, preliminary findings show promising signs of stabilizing insulin levels in PMOS patients and thereby restoring sex hormone balance.

An echo of Sydney's 2024 institutional buy-up

Advocates emphasize that these comorbidities are highly prevalent among women with PMOS, reinforcing the rationale behind the name change: to shift focus toward the metabolic underpinnings of the disorder. Previously, the name Polycystic Ovarian Syndrome implied that patients must have cysts on the ovaries to be diagnosed, which placed undue emphasis on ovarian morphology rather than the broader metabolic and hormonal health of the patient.

In reality, the ovaries in a person with PMOS often do not have classic cysts but instead exhibit an excess of follicles - small fluid-filled sacs that secrete hormones. The testosterone excess arises from insulin resistance or impaired sugar metabolism.

What auditors flagged in the May filing

Developing a single, definitive treatment for PMOS remains challenging due to the heterogeneity of symptoms and the complexities of designing clinical trials for reproductive conditions. The FDA requires clear, measurable endpoints, which are difficult to establish for a syndrome with such diverse presentations.

While a drug could theoretically target a specific symptom like hirsutism, it must prove superior to existing therapies to gain approval. The larger hurdle is creating trials to evaluate GLP-1s for the hormonal imbalance and infertility aspects of PMOS.